Yoshikazu Sugimoto

发表

Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors.

Xin Wang, T. Furukawa, S. Akiyama, 2003, Molecular pharmacology.

Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants

Y. Sugimoto, Satomi Tsukahara, Y. Imai, 2003, International journal of cancer.

Antimitotic activity and reversal of breast cancer resistance protein-mediated drug resistance by stilbenoids from Bletilla striata.

Hiroshi Morita, Jun'ichi Kobayashi, Yoshikazu Sugimoto, 2005, Bioorganic & medicinal chemistry letters.

Breast cancer resistance protein exports sulfated estrogens but not free estrogens.

Takashi Tsuruo, T. Tsuruo, Y. Sugimoto, 2003, Molecular pharmacology.

ABCG2 Transports Sulfated Conjugates of Steroids and Xenobiotics*

Yuichi Sugiyama, Y. Sugiyama, Y. Sugimoto, 2003, Journal of Biological Chemistry.

Gene Expression Signature and the Prediction of Ulcerative Colitis–Associated Colorectal Cancer by DNA Microarray

Tsuyoshi Konishi, Shin Sasaki, Junichiro Tanaka, 2007, Clinical Cancer Research.

Modification of pyrimidine derivatives from antiviral agents to antitumor agents.

Yoshimasa Uehara, Takahiro Katoh, Takao Yamori, 2006, Anticancer research.

Distal colorectal cancers with microsatellite instability (MSI) display distinct gene expression profiles that are different from proximal MSI cancers.

Shin Sasaki, Junichiro Tanaka, Toshinori Oka, 2006, Cancer research.

Phytoestrogens/Flavonoids Reverse Breast Cancer Resistance Protein/ABCG2-Mediated Multidrug Resistance

Y. Sugimoto, Satomi Tsukahara, Y. Imai, 2004, Cancer Research.

Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport.

S. Bates, R. Robey, Zhe-Sheng Chen, 2003, Cancer research.

Induction of cellular resistance to nucleoside reverse transcriptase inhibitors by the wild-type breast cancer resistance protein.

Xin Wang, T. Furukawa, S. Akiyama, 2004, Biochemical pharmacology.

Estrogen‐mediated post transcriptional down‐regulation of P‐glycoprotein in MDR1‐transduced human breast cancer cells

Y. Sugimoto, Satomi Tsukahara, J. Mitsuhashi, 2006, Cancer science.

p53-defective tumors with a functional apoptosome-mediated pathway: a new therapeutic target.

Takashi Tsuruo, Hiroshi Tomoda, Jun-ichi Hamada, 2005, Journal of the National Cancer Institute.

mTOR signaling mediates resistance to tankyrase inhibitors in Wnt-driven colorectal cancer

Yukiko Muramatsu, H. Seimiya, T. Mashima, 2017, Oncotarget.